We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+16.35%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$239M
AUM Growth
-$103M
Cap. Flow
-$106M
Cap. Flow %
-44.2%
Top 10 Hldgs %
35.32%
Holding
114
New
39
Increased
6
Reduced
19
Closed
45

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.8M
2
HCA icon
HCA Healthcare
HCA
+$3.62M
3
HOLX
Hologic
HOLX
+$3.59M
4
ZGNX
Zogenix, Inc.
ZGNX
+$3.47M
5
MDT icon
Medtronic
MDT
+$3M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.9M
2
CNC icon
Centene
CNC
+$7.74M
3
AGN
Allergan plc
AGN
+$7.17M
4
DXCM icon
DexCom
DXCM
+$6.24M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$6.22M

Sector Composition

Rank Sector Weight
1 Healthcare 46.43%
2 Industrials 2.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEN icon
51
Penumbra
PEN
$12.8B
$1.41M 0.59%
15,000
-44,579
-75% -$4.42M
ARGX icon
52
argenx
ARGX
$54.1B
$1.29M 0.54%
+20,400
New +$668K
ACER
53
DELISTED
Acer Therapeutics Inc
ACER
$1.26M 0.53%
+90,660
New +$1.48M
TSRO
54
DELISTED
TESARO, Inc.
TSRO
$1.24M 0.52%
+15,000
New +$1.47M
BHVN
55
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.14M 0.48%
+42,186
New +$1.16M
QTRX icon
56
Quanterix
QTRX
$190M
$1.06M 0.44%
+49,300
New +$962K
PBYI icon
57
Puma Biotechnology
PBYI
$454M
$989K 0.41%
+10,000
New +$1.12M
ARNA
58
DELISTED
Arena Pharmaceuticals Inc
ARNA
$951K 0.4%
27,983
-83,717
-75% -$2.38M
GYRE icon
59
Gyre Therapeutics
GYRE
$744M
$818K 0.34%
+8,000
New +$408K
STDY
60
DELISTED
SteadyMed Ltd
STDY
$796K 0.33%
215,214
– –
KURA icon
61
Kura Oncology
KURA
$850M
$765K 0.32%
+50,000
New +$737K
ACOR
62
DELISTED
Acorda Therapeutics
ACOR
$751K 0.31%
+292
New +$830K
ABLX
63
DELISTED
Ablynx NV
ABLX
$735K 0.31%
+29,399
New +$664K
KDMN
64
DELISTED
Kadmon Holdings, Inc.
KDMN
$724K 0.3%
+200,000
New +$714K
CHRS icon
65
CALL
Coherus Oncology
CHRS
$196M
$440K 0.18%
+50,000
New +$535K
CHRS icon
66
Coherus Oncology
CHRS
$196M
$220K 0.09%
+25,000
New +$268K
NSTG
67
CALL
DELISTED
NanoString Technologies, Inc.
NSTG
$219K 0.09%
29,300
-70,700
-71% -$670K
AGEN
68
CALL
Agenus
AGEN
$290M
$214K 0.09%
+3,347
New +$255K
FOMX
69
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$145K 0.06%
24,100
– –
ABT icon
70
CALL
Abbott
ABT
$187B
– –
-75,000
Closed -$4M
AZTA icon
71
Azenta
AZTA
$1.48B
– –
-95,000
Closed -$2.88M
BAX icon
72
PUT
Baxter International
BAX
$14.2B
– –
-135,000
Closed -$8.47M
BCRX icon
73
BioCryst Pharmaceuticals
BCRX
$2.4B
– –
-150,000
Closed -$786K
BIO icon
74
Bio-Rad Laboratories Class A
BIO
$9.42B
– –
-28,000
Closed -$6.22M
BMY icon
75
CALL
Bristol-Myers Squibb
BMY
$132B
– –
-100,000
Closed -$6.37M
1 2
3
4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
ONGA
O'Neil Global Advisors Los Angeles, California $14.4M AUM 220.73% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM

Pura Vida Investments's Q4 2017 Portfolio in Review

As of Q4 2017, Pura Vida Investments held 114 positions worth $239M, down 30% from $342M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Pura Vida Investments withdrew a net $106M in Q4 2017, closing 45 positions and reducing 19 holdings. Its most notable exit was Merck, an estimated $9.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 50% a quarter earlier, followed by Industrials.

Against the trend, Pura Vida Investments opened a new position in BioMarin Pharmaceuticals worth $3.9M.

  • Pura Vida Investments's largest Q4 2017 buy was BioMarin Pharmaceuticals: 43,700 shares worth $3.9M.
  • Pura Vida Investments added most to Zogenix, Inc. in Q4 2017, an estimated $3.47M increase.
  • Pura Vida Investments's biggest Q4 2017 reduction was LivaNova, cutting an estimated $5.1M.
  • Pura Vida Investments fully exited Merck in Q4 2017, selling an estimated $9.9M.
  • Pura Vida Investments's ten largest holdings make up 35% of its $239M portfolio in Q4 2017.
  • Pura Vida Investments opened 39 new positions and closed 45 in Q4 2017.
  • Pura Vida Investments's portfolio value fell 30% quarter-over-quarter to $239M.

Based on Pura Vida Investments's 13F filing for Q4 2017, filed 14 Feb 2018.